RARE DISEASE
Full NF2-related schwannomatosis
Full NF2-related schwannomatosis
Full NF2-related schwannomatosis
Synonyms: Full NF2, Full neurofibromatosis type 2, Nonmosaic NF2-related schwannomatosis, Nonmosaic neurofibromatosis type 2
Synonyms: Full NF2, Full neurofibromatosis type 2, Nonmosaic NF2-related schwannomatosis, Nonmosaic neurofibromatosis type 2
Synonyms: Full NF2, Full neurofibromatosis type 2, Nonmosaic NF2-related schwannomatosis, Nonmosaic neurofibromatosis type 2
Drug discovery
6
drugs
With orphan designations
Overview
NF2-related schwannomatosis (NF2-SWN) is an autosomal dominant disorder caused by pathogenic NF2 gene variants, leading to Merlin tumor suppressor protein dysfunction. It manifests with bilateral vestibular schwannomas, meningiomas, and ependymomas, causing hearing loss, neurological deficits, and visual impairment. Diagnosis relies on clinical criteria (e.g., bilateral vestibular schwannomas), neuroimaging, and genetic testing. Tumorigenesis involves disrupted Hippo/YAP signaling and aberrant cell proliferation. Management includes surveillance and multimodal therapies targeting tumor growth [1][6][12].
Therapies
Surgical resection or stereotactic radiosurgery for symptomatic tumors [3][16][20].
Molecular therapies (e.g., brigatinib, ALK/FAK inhibitors) showing tumor stabilization in clinical trials [3][13][19].
Investigational approaches: antisense oligonucleotides, gene therapy, and combination therapies [8][10][13].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare neoplastic diseases, rare neurological diseases, rare ophthalmic disorders, rare otorhinolaryngological diseases, rare transplant-related disorders
Research Papers
534 drug discovery papers about Full NF2-related schwannomatosis, with 9 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
534 drug discovery papers about Full NF2-related schwannomatosis, with 9 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-22 | Pilot Evaluation of Targets in Neurofibromatosis Type 2: Drug Potency and Viability Analysis by the S' Metric
A pilot investigatoin into NF2 disease drug discovery data in mouse high throughput screening data from CENIX. HSP90 drug molecules were demonstrated as promising while using multiple endpoints, and alternative interpretation methods for working with dose response curve data are presented.
2026-06-23 | Audiologic Outcomes with Auditory Brainstem Implantation Including Successful Open Set Speech Perception with Bilateral Implantation
Background/Objectives: For patients with profound deafness resulting from auditory nerve pathology, as in Neurofibromatosis type 2, auditory brainstem implantation (ABI) can restore meaningful acoustic input. The literature reporting real-world results for ABI users is limited, especially regarding patients with bilateral implants. Here, we provide an updated report on the audiologic outcomes among all ABI patients treated at a tertiary institution, including high-performing bilateral ABI users. Methods: In this updated and expanded retrospective case series, audiologic outcomes were reviewed in sixteen consecutive patients who underwent ABI placement by a single neurosurgeon-neurotologist team at our center since 2018. Implantation in four of these patients was on their second side after having undergone first side implantation prior to receiving care at our hospital. Main outcome measures were sound awareness (sound-field threshold testing) and speech understanding (pattern perception, spondee, open-set speech testing). Results: Sound awareness was achieved in 100% of patients (16/16) using an average of 12 electrodes (range 7–20). Persistent non-auditory sensations were reported by 12.5% (2/16). Postoperative speech differentiation (with or without lip-reading) was experienced in 87.5% (14/16). Two second-sided ABI recipients experienced exceptional outcomes as high-performing outliers: one achieved 57% audio only and 86% audio + visual hearing in noise test (HINT) sentence scores; the second bilateral user scored 92% with auditory-only input. Conclusions: ABI represents a viable option for patients who are at risk of developing bilateral profound deafness resulting from auditory nerve disruption. Second sided device implantation is safe and has the potential to significantly improve auditory outcomes.
2026-06-17 | Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT).
To date, there is no proven licensed systemic treatment for neurofibromatosis type 2 (NF2)-related schwannomatosis patients. There is a need for more effective, less toxic treatments and, as a rare disease, NF2 is often overlooked in targeted drug development. Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV-ritonavir and lopinavir (Kaletra and Norvir)-that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures. The safety and tolerability of these drugs are already known, so they are safe candidates to trial in NF2 patients. This trial is an open-label, phase 0 design. A maximum of 16 participants diagnosed with NF2-related schwannomatosis will be enrolled in this study. Treatment duration is 30 days, with a 30-day follow-up. Biopsies and blood samples will be collected to assess whether the drugs reach the tumours and to analyse the tumour-cell response. The primary outcome is pharmacodynamic response, defined as a statistically significant decrease in biomarker activity in CS biopsy samples at day 30. The sample size calculation is based on the tissue biomarker response. The study was approved by an Ethics Committee (West of Scotland Research Ethics Service (23/WS/0178)), the Health Research Authority (HRA), the Medicines and Healthcare products Regulatory Authority (MHRA) and each of the participating NHS Trust's Research and Development departments. Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. ISRCTN10422213.
2026-05-29 | Comprehensive characterization of spinal ependymomas in NF2-Schwannomatosis.
Spinal ependymomas (SE) account for 10% of ependymomas and are the most frequent spinal glial tumors. NF2-related Schwannomatosis (NF2-SWN) patients are predisposed to multiple SE in addition to other tumors, schwannomas and meningiomas. Surgery remains the main treatment option, but mays lead to severe morbidity. In many cases, it is the cystic rather than the solid component of the tumor that drives neurological symptoms and ultimately necessitates surgical intervention. Understanding tumor and associated cyst formation is therefore important to develop new therapeutic approaches. This clinical and radiological study includes 33 NF2-SWN with a long-term follow-up and 11 sporadic SE patients. Tumor and cyst characteristics were assessed, and histopathological analyses performed, including multiplex immunohistochemistry and RNA sequencing. Radiological analysis revealed that peritumoral edema frequently precedes cystic formation. Histological analysis showed that macrophage infiltration, particularly by SPP1-positive macrophages, was associated with cystic growth in NF2-SWN SE. RNAseq analysis identified distinct immune microenvironments differentiating NF2-SWN from sporadic SE, including differences in VEGF-C expression. Consistent with these results, AXITINIB, a selective inhibitor of VEGFR and VEGFR3 which acts as the receptor for VEGF-C, was proposed to a NF2-SWN patient with a progressing cystic SE and resulted in clinical improvement accompanied by a reduction in the peritumoral cyst. These results support a role for VEGF signaling and macrophage-mediated microenvironmental changes in edema and cystic growth of NF2-SWN SE. The observed clinical response to AXITINIB in an index patient suggests that new combinations of anti-angiogenic therapies may represent a promising early targeted approach.
2026-05-17 | A review of targeted therapies for NF2-related vestibular schwannoma: molecular pathogenesis, emerging therapeutics, and future clinical horizons.
Neurofibromatosis type 2 (NF2) is a hereditary tumor syndrome driven by mutations in the NF2 gene. The mutation leads to aberrant proliferation of Schwann cells along the vestibular division of cranial nerve VIII, resulting in bilateral vestibular schwannomas (VS) that cause progressive hearing loss and neurological dysfunction. Loss of the tumor suppressor merlin results in dysregulation of multiple oncogenic pathways, including VEGF, MAPK/ERK, PI3K/AKT/mTOR, EGFR/ErbB, PDGFR, and Hippo-YAP. The inability of conventional management modalities to address the multifocal and progressive nature of NF2-associated tumors has driven investigation into targeted therapies. This review summarizes the evolving landscape of targeted therapies in NF2-associated vestibular schwannomas. Management of NF2-VS is individualized, with active surveillance favored for stable or smaller tumors, surgical resection pursued for symptomatic or enlarging lesions, and bevacizumab increasingly utilized as either a primary or adjunctive systemic option. Radiation therapy, by contrast, is employed selectively given its potential to compromise auditory function and its association with malignant transformation. Targeted agents such as bevacizumab (anti-VEGF), MEK inhibitors (selumetinib, trametinib), EGFR inhibitors (lapatinib, erlotinib), and mTOR inhibitors (everolimus) are examined across preclinical models and clinical trials. Emerging approaches including dual pathway inhibition and immunologic strategies such as VEGF receptor vaccination are also discussed. Importantly, NF2-VS exhibits molecular and clinical heterogeneity, with differing responses observed across pediatric and adult populations. Therapeutic limitations of current targeted therapies include resistance, toxicity, and the modest efficacy of monotherapies. As such, future investigations must refine endpoints (e.g., hearing stabilization vs. tumor regression), optimize dosing strategies, and personalize therapy based on age, tumor biology, and clinical trajectory. This review highlights the translational challenges and opportunities that lie ahead in delivering clinically efficacious therapies specific to each patient.
2026-07-22 | Pilot Evaluation of Targets in Neurofibromatosis Type 2: Drug Potency and Viability Analysis by the S' Metric
A pilot investigatoin into NF2 disease drug discovery data in mouse high throughput screening data from CENIX. HSP90 drug molecules were demonstrated as promising while using multiple endpoints, and alternative interpretation methods for working with dose response curve data are presented.
2026-06-23 | Audiologic Outcomes with Auditory Brainstem Implantation Including Successful Open Set Speech Perception with Bilateral Implantation
Background/Objectives: For patients with profound deafness resulting from auditory nerve pathology, as in Neurofibromatosis type 2, auditory brainstem implantation (ABI) can restore meaningful acoustic input. The literature reporting real-world results for ABI users is limited, especially regarding patients with bilateral implants. Here, we provide an updated report on the audiologic outcomes among all ABI patients treated at a tertiary institution, including high-performing bilateral ABI users. Methods: In this updated and expanded retrospective case series, audiologic outcomes were reviewed in sixteen consecutive patients who underwent ABI placement by a single neurosurgeon-neurotologist team at our center since 2018. Implantation in four of these patients was on their second side after having undergone first side implantation prior to receiving care at our hospital. Main outcome measures were sound awareness (sound-field threshold testing) and speech understanding (pattern perception, spondee, open-set speech testing). Results: Sound awareness was achieved in 100% of patients (16/16) using an average of 12 electrodes (range 7–20). Persistent non-auditory sensations were reported by 12.5% (2/16). Postoperative speech differentiation (with or without lip-reading) was experienced in 87.5% (14/16). Two second-sided ABI recipients experienced exceptional outcomes as high-performing outliers: one achieved 57% audio only and 86% audio + visual hearing in noise test (HINT) sentence scores; the second bilateral user scored 92% with auditory-only input. Conclusions: ABI represents a viable option for patients who are at risk of developing bilateral profound deafness resulting from auditory nerve disruption. Second sided device implantation is safe and has the potential to significantly improve auditory outcomes.
2026-06-17 | Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT).
To date, there is no proven licensed systemic treatment for neurofibromatosis type 2 (NF2)-related schwannomatosis patients. There is a need for more effective, less toxic treatments and, as a rare disease, NF2 is often overlooked in targeted drug development. Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV-ritonavir and lopinavir (Kaletra and Norvir)-that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures. The safety and tolerability of these drugs are already known, so they are safe candidates to trial in NF2 patients. This trial is an open-label, phase 0 design. A maximum of 16 participants diagnosed with NF2-related schwannomatosis will be enrolled in this study. Treatment duration is 30 days, with a 30-day follow-up. Biopsies and blood samples will be collected to assess whether the drugs reach the tumours and to analyse the tumour-cell response. The primary outcome is pharmacodynamic response, defined as a statistically significant decrease in biomarker activity in CS biopsy samples at day 30. The sample size calculation is based on the tissue biomarker response. The study was approved by an Ethics Committee (West of Scotland Research Ethics Service (23/WS/0178)), the Health Research Authority (HRA), the Medicines and Healthcare products Regulatory Authority (MHRA) and each of the participating NHS Trust's Research and Development departments. Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. ISRCTN10422213.
2026-05-29 | Comprehensive characterization of spinal ependymomas in NF2-Schwannomatosis.
Spinal ependymomas (SE) account for 10% of ependymomas and are the most frequent spinal glial tumors. NF2-related Schwannomatosis (NF2-SWN) patients are predisposed to multiple SE in addition to other tumors, schwannomas and meningiomas. Surgery remains the main treatment option, but mays lead to severe morbidity. In many cases, it is the cystic rather than the solid component of the tumor that drives neurological symptoms and ultimately necessitates surgical intervention. Understanding tumor and associated cyst formation is therefore important to develop new therapeutic approaches. This clinical and radiological study includes 33 NF2-SWN with a long-term follow-up and 11 sporadic SE patients. Tumor and cyst characteristics were assessed, and histopathological analyses performed, including multiplex immunohistochemistry and RNA sequencing. Radiological analysis revealed that peritumoral edema frequently precedes cystic formation. Histological analysis showed that macrophage infiltration, particularly by SPP1-positive macrophages, was associated with cystic growth in NF2-SWN SE. RNAseq analysis identified distinct immune microenvironments differentiating NF2-SWN from sporadic SE, including differences in VEGF-C expression. Consistent with these results, AXITINIB, a selective inhibitor of VEGFR and VEGFR3 which acts as the receptor for VEGF-C, was proposed to a NF2-SWN patient with a progressing cystic SE and resulted in clinical improvement accompanied by a reduction in the peritumoral cyst. These results support a role for VEGF signaling and macrophage-mediated microenvironmental changes in edema and cystic growth of NF2-SWN SE. The observed clinical response to AXITINIB in an index patient suggests that new combinations of anti-angiogenic therapies may represent a promising early targeted approach.
2026-05-17 | A review of targeted therapies for NF2-related vestibular schwannoma: molecular pathogenesis, emerging therapeutics, and future clinical horizons.
Neurofibromatosis type 2 (NF2) is a hereditary tumor syndrome driven by mutations in the NF2 gene. The mutation leads to aberrant proliferation of Schwann cells along the vestibular division of cranial nerve VIII, resulting in bilateral vestibular schwannomas (VS) that cause progressive hearing loss and neurological dysfunction. Loss of the tumor suppressor merlin results in dysregulation of multiple oncogenic pathways, including VEGF, MAPK/ERK, PI3K/AKT/mTOR, EGFR/ErbB, PDGFR, and Hippo-YAP. The inability of conventional management modalities to address the multifocal and progressive nature of NF2-associated tumors has driven investigation into targeted therapies. This review summarizes the evolving landscape of targeted therapies in NF2-associated vestibular schwannomas. Management of NF2-VS is individualized, with active surveillance favored for stable or smaller tumors, surgical resection pursued for symptomatic or enlarging lesions, and bevacizumab increasingly utilized as either a primary or adjunctive systemic option. Radiation therapy, by contrast, is employed selectively given its potential to compromise auditory function and its association with malignant transformation. Targeted agents such as bevacizumab (anti-VEGF), MEK inhibitors (selumetinib, trametinib), EGFR inhibitors (lapatinib, erlotinib), and mTOR inhibitors (everolimus) are examined across preclinical models and clinical trials. Emerging approaches including dual pathway inhibition and immunologic strategies such as VEGF receptor vaccination are also discussed. Importantly, NF2-VS exhibits molecular and clinical heterogeneity, with differing responses observed across pediatric and adult populations. Therapeutic limitations of current targeted therapies include resistance, toxicity, and the modest efficacy of monotherapies. As such, future investigations must refine endpoints (e.g., hearing stabilization vs. tumor regression), optimize dosing strategies, and personalize therapy based on age, tumor biology, and clinical trajectory. This review highlights the translational challenges and opportunities that lie ahead in delivering clinically efficacious therapies specific to each patient.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
6 orphan drug designations for Full NF2-related schwannomatosis.
6 orphan drug designations for Full NF2-related schwannomatosis.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Non-replicating recombinant adeno-associated virus carrying the human neurofibromin 2 (NF2) transgene (scAAV9.P400.NF2) | gene therapies | FDA | 2026-07-14 | — | Nationwide Children’s Hospital |
4-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazol-5-amine | small molecules | EMA | 2024-12-13 | — | Opis S.r.l. |
bevacizumab | antibodies | FDA | 2024-07-15 | — | DELBERT SAS |
Trineumin | small molecules | FDA | 2023-01-09 | — | PRG S&T Co., Ltd |
bortezomib | small molecules | FDA | 2016-07-05 | — | BioXcel Corporation |
N-hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide | small molecules | EMA | 2012-04-26 | — | Propharma Group The Netherlands B.V. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.